Share-based Payment Arrangement, Expense of Arcutis Biotherapeutics, Inc. from 31 Dec 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Arcutis Biotherapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 31 Dec 2025.
  • Arcutis Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $10,062,000, a 13% increase year-over-year.
  • Arcutis Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $40,364,000, a 3.3% decline year-over-year.
  • Arcutis Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $40,364,000, a 3.3% decline from 2024.
  • Arcutis Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $41,730,000, a 7.5% increase from 2023.
  • Arcutis Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $38,813,000, a 19% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Arcutis Biotherapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $40,364,000 $10,062,000 +$1,126,000 +13% 01 Oct 2025 31 Dec 2025 10-K 25 Feb 2026 2025 FY
Q3 2025 $39,238,000 $10,035,000 -$206,000 -2% 01 Jul 2025 30 Sep 2025 10-Q 28 Oct 2025 2025 Q3
Q2 2025 $39,444,000 $10,489,000 -$2,034,000 -16% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $41,478,000 $9,778,000 -$252,000 -2.5% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $41,730,000 $8,936,000 +$179,000 +2% 01 Oct 2024 31 Dec 2024 10-K 25 Feb 2026 2025 FY
Q3 2024 $41,551,000 $10,241,000 +$242,000 +2.4% 01 Jul 2024 30 Sep 2024 10-Q 28 Oct 2025 2025 Q3
Q2 2024 $41,309,000 $12,523,000 +$1,945,000 +18% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $39,364,000 $10,030,000 +$551,000 +5.8% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $38,813,000 $8,757,000 -$507,000 -5.5% 01 Oct 2023 31 Dec 2023 10-K 25 Feb 2026 2025 FY
Q3 2023 $39,320,000 $9,999,000 +$1,210,000 +14% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $38,110,000 $10,578,000 +$2,482,000 +31% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $35,628,000 $9,479,000 +$2,946,000 +45% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $32,682,000 $9,264,000 +$3,578,000 +63% 01 Oct 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
Q3 2022 $29,104,000 $8,789,000 +$3,426,000 +64% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $25,678,000 $8,096,000 +$3,756,000 +87% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $21,922,000 $6,533,000 -$1,970,000 -23% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $23,892,000 $5,686,000 +$3,043,000 +115% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $20,849,000 $5,363,000 +$3,102,000 +137% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $17,747,000 $4,340,000 +$2,291,000 +112% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $15,456,000 $8,503,000 +$7,513,000 +759% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $7,943,000 $2,643,000 +$2,173,000 +462% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $5,770,000 $2,261,000 +$2,122,000 +1527% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $3,648,000 $2,049,000 +$1,910,000 +1374% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $1,738,000 $990,000 +$914,000 +1203% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $824,000 $470,000 01 Oct 2019 31 Dec 2019 10-K 22 Feb 2022 2021 FY
Q3 2019 $139,000 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $139,000 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $76,000 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1

Arcutis Biotherapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $40,364,000 -$1,366,000 -3.3% 01 Jan 2025 31 Dec 2025 10-K 25 Feb 2026 2025 FY
2024 $41,730,000 +$2,917,000 +7.5% 01 Jan 2024 31 Dec 2024 10-K 25 Feb 2026 2025 FY
2023 $38,813,000 +$6,131,000 +19% 01 Jan 2023 31 Dec 2023 10-K 25 Feb 2026 2025 FY
2022 $32,682,000 +$8,790,000 +37% 01 Jan 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
2021 $23,892,000 +$15,949,000 +201% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $7,943,000 +$7,119,000 +864% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $824,000 +$673,000 +446% 01 Jan 2019 31 Dec 2019 10-K 22 Feb 2022 2021 FY
2018 $151,000 01 Jan 2018 31 Dec 2018 10-K 16 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.